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Abstract
A rapid, sensitive and specific method for quantifying hydroxocobalamin in human plasma using paracetamol 
as the internal standard (IS) is described. The analyte and the IS were extracted from plasma by liquid-liquid 
extraction using an organic solvent (ethanol 100%; -20°C). The extracts were analyzed by high performance liquid 
chromatography coupled with electrospray tandem mass spectrometry (HPLC-MS-MS). Chromatography was 
performed on Prevail C8 3 μm, analytical column (2.1×100 mm i.d.). The method had a chromatographic run time 
of 3.4 min and a linear calibration curve over the range 5-400 ng.mL-1 (r>0.9983). The limit of quantification was 5 
ng.mL-1. The method was also validated without the use of the internal standard. The precision in the intra-batch 
validation with IS was 9.6%, 8.9%, 1.0% and 2.8% whereas without IS was 9.2%, 8.2%, 1.8% and 1.5% for 5, 15, 80 
and 320 ng/mL, respectively. The accuracy in intra-batch validation with IS was 108.9%, 99.9%, 98.9% and 99.0% 
whereas without IS was 101.1%, 99.3%, 97.5% and 92.5% for 5, 15, 80 and 320 ng/mL, respectively. The precision 
in the inter-batch validation with IS was 9.4%, 6.9%, 4.6% and 5.5% whereas without IS was 10.9%, 6.4%, 5.0% 
and 6.2% for 5, 15, 80 and 320 ng/mL, respectively. The accuracy in inter-batch validation with IS was 101.9%, 
104.1%, 103.2% and 99.7% whereas without IS was 94.4%, 101.2%, 101.6% and 96.0% for 5, 15, 80 and 320 ng/
mL, respectively. This HPLC-MS-MS procedure was used to assess the pharmacokinetics of cobalamin following 
intramuscular injection 5000 μg in healthy volunteers of both sexes (10 males and 10 females). The volunteers 
had the following clinical characteristics (according to gender and expressed as mean ± SD [range]): males: age: 
32.40 ± 8.00 [23.00-46.00], height: 1.73 ± 0.07 m [1.62-1.85], body weight: 72.48 ± 10.22 [60.20-88.00]; females: 
age: 28.60 ± 9.54 [18.00-44.00], height: 1.60 ± 0.05 [1.54-1.70], body weight: 58.64 ± 6.09 [51.70-66.70]. The 
following pharmacokinetic parameters were obtained from the hydroxocobalamin plasma concentration vs. time 
curves: AUClast, T1/2, Tmax, Vd, Cl, Cmax and Clast. The pharmacokinetic parameters were 120 (± 25) ng.mL
-1 for Cmax, 
2044 (± 641) ng.hr.mL-1 for AUClast, 8 (± 3.2) ng.mL
-1 for Clast, 38 (± 15.8) hr for T1/2 and 2.5 (range 1-6) hr for Tmax. 
Female volunteers presented significant (p=0.0136) lower AUC (1706 ± 704) ng.hr.mL-1) and larger (p=0.0205) 
clearance (2.91 ± 1.41 L/hr), as compared to male 2383 ± 343 ng.hr.mL-1 and 1.76 ± 0.23 L/hr, respectively. These 
pharmacokinetic differences could explain the higher prevalence of vitamin B12 deficiency in female patients. The 
method described validated well without the use of the internal standard and this approach should be investigated 
in other HPLC-MS-MS methods.
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Introduction
Cobalamin is necessary for the development of red blood cells, 
growth and nervous system maintenance [1]. It is present in animal 
products such as eggs, milk, fish and meat [1]. The dietary need for 
adults and infants are 1.5 ug (1 to 2 ug) and 0.4 ug per day, respectively 
[1,2]. Cobalamin plasma levels are considered normal between 0.2 
and 0.9 ng/mL2. There are two different forms of administration for 
intramuscular vitamin B12: cyanocobalamin and hydroxocobalamin 
[1]. The hydroxocobalamin is the choice for intramuscular 
administration since it is more bioavailable than the water solution 
of cyanocobalamin, it is retained in the body longer and requires less 
frequent dosage [1,3]. This is due to the extensively bind to plasma 
proteins and the long half-life [3].
Hydroxocobalamin has been determined in human and rat plasma 
by isotopic dilution [4,5], in nutritive supplements and chlorella 
foods by capillary electrophoresis-inductively coupled plasma mass 
spectrometry [6]  and in ovine tissues by high-performance liquid 
chromatography [7]. Here we describe a fast, sensitive, and specific 
method for quantification of hydroxocobalamin in human plasma 
using high-performance liquid chromatography coupled with 
tandem mass spectrometry (HPLC-MS-MS), with paracetamol as 
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the internal standard. This method was subsequently used to assess 
the pharmacokinetic profile in healthy volunteers of both sexes (10 
males and 10 females) of one injectable (intramuscular) vitamin B12 
formulation (injectable solution of alfa 5,6-dimethylbenzimidazolyl 
pyrrolidone cobamide; 2.5 mL of 2.000 ug/mL solution). 
Methods
Calibration standards and quality controls
Stock solutions of hydroxocobalamin and the IS were prepared in 
methanol-water (50:50 v/v) at concentrations of 1 mg/mL. Calibration 
curves of hydroxocobalamin were prepared by spiking blank plasma at 
concentrations of 5, 10, 20, 50, 100, 200, 300 and 400 ng/mL and the 
analysis was carried out in duplicate for each concentration. The quality 
control samples were prepared in blank plasma at concentrations 
of 15.0, 80.0 and 320.0 ng/mL (Low, intermediate and high quality-
control samples, respectively). The spiked plasma samples (standards 
and quality controls) were extracted on each analytical batch along 
with the unknown samples.
Drug, chemicals and reagents
Hydroxocobalamin was provided by Genix Indústria Farmacêutica 
Ltda, Brazil (lot number 507610360). Paracetamol was provided by 
Anqiu Luan Pharmaceutical China (lot number 0640720). Acetonitrile 
(HPLC grade), ethanol (HPLC grade), methanol (HPLC grade), formic 
acid (88%; Analysis Grade) and ammonium acetate (Analysis Grade) 
were purchased from Mallinckrodt (USA). Ultra pure water was 
obtained from an Elga UHQ system (UK). Blank human blood was 
collected from healthy, drug-free volunteers. Plasma was obtained by 
centrifugation of blood treated with the anticoagulant sodium heparin. 
Pooled plasma was prepared and stored at approximately -20ºC until 
needed.
Drug analysis
The blood samples were centrifuged at approximately 2000 g for 1 
min at 4°C, and the decanted plasma stored at -20°C until assayed for 
hydroxocobalamin contents.
The extraction was performed by vortex-mixing 200 μL of each 
plasma sample, placed in glass tubes followed by the internal standard 
(50 μL of paracetamol at 1 μg/mL), with 1 mL of an organic solvent 
(ethanol 100%; -20°C) and vortexed for 40 s. The sample was centrifuged 
at 2000 g for 5 min. The upper organic phase was transferred to another 
set of clean glass tubes and evaporated until dry under N2 at 50°C. The 
dry residues were dissolved with 0.2 mL of acetonitrile/water (50/50; 
v/v)+10 mM ammonium acetate+0.1% of formic acid and vortexed for 
10 s. 
Chromatographic conditions
An aliquot (10 μL) of each plasma extract was injected into a Prevail 
C8 3 um, analytical column (2.1×100 mm i.d.). The compounds were 
eluted by pumping the mobile phase at a flow rate of 600 uL/min, and a 
post-column split (1:2) was introduced. Under these conditions, typical 
standard retention times were 1.55 min for hydroxocobalamin and 2.18 
min for paracetamol, and back-pressure values of approximately 70 bar 
were observed. The temperature of the auto-sampler was maintained at 
6ºC ± 2 and the run-time was 3.4 min.
The method requires an additional time (0.5 min) to inject a 
new sample since the auto sampler takes 0.5 min to inject a sample. 
This additional time allowed for finishing the equilibrium between 
injections. The mobile phase was acetonitrile:water (50:50 v/v) + 10 
mM ammonium acetate + 0.1% formic acid.
Mass-spectrometric conditions
The mass spectrometer (API 4000) equipped with an electrospray 
source in positive mode (ES+), was set up in Multiple Reaction 
Monitoring (MRM), monitoring the transitions 359.20>147.10 and 
152.00>110.00, for hydroxocobalamin and IS, respectively. Figure 1 
shows the full scan spectra (upper trace) and the product ion spectra 
(lower trace) obtained for hydroxocobalmin. The source block 
temperature was set at 400°C and the turboionspray capillary voltage 
to 5.0 kV. For both hydroxocobalamin and internal standard, the 
following optimized parameters were obtained: for hydroxocobalamin 
the declustering potential, collision energy and collision exit potential 
were 139 (V), 29 (eV) and 12 (V), respectively. The corresponding 
values for internal standard were 66 (V), 23 (eV) and 8 (V), respectively. 
Data were acquired by Analyst software (1.4.1, Applied Biosystems, 
Foster City, CA, USA). 
Method development  
Linearity was determined to assess the performance of the method. 
A linear least-squares regression with a weighting index of 1/x2 was 
performed on the peak area ratios of hydroxocobalamin and IS vs. 
hydroxocobalamin concentrations of the eight plasma standards (5, 
10, 20, 50, 100, 200, 300 and 400 ng/mL) in duplicate to generate a 
calibration curve.
The recovery was evaluated by dividing the extracted sample mean 
by the unextracted (spiked blank plasma extract residues) sample mean 
of the corresponding concentration. The matrix effect experiments 
were performed using the ratio between spiked mobile phase solutions 
and spiked plasma residues (drug-free plasma extracts).
There were performed 3 validations in time different. Each 
validation had 7 samples for limit of quantification and quality controls. 
Within- and between-run precision was determined as the relative 
standard deviation, RSD(%)=100(SD/M), where M is the mean, SD is 
the standard deviation of M. Accuracy was calculated as the percentage 
relative error, RE(%)=(E-T)(100/T), where E is the experimentally 
determined concentration and T is the nominal concentration. 
Stability
Stability quality control plasma samples (15.0, 80.0 and 320.0 ng/
mL for hydroxocobalamin) were subjected to short-term (8 h 30 min) 
room temperature, three freeze/thaw (-20 to 25°C) cycles and 72 h 30 
min auto-sampler stability (6°C). Subsequently, the hydroxocobalamin 
concentrations were measured compared to freshly prepared samples.
Clinical protocol
Twenty healthy volunteers of both sexes between 18 and 50 years of 
age and within 15% of the ideal body weight were selected for the study 
after having their health status previously assessed by clinical evaluation 
(physical examination, ECG) and the following laboratory tests: blood 
glucose, urea, creatinine, AST, ALT, alkaline phosphatase, -GT, total 
bilirubins, albumin and total proteins, triglycerides, total cholesterol, 
hemoglobin, hematocrit, total and differential white cell counts, and 
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Figure 1: Full scan mass spectra in upper trace (A) and product ion spectra in lower trace (B) of hydroxocobalamin.
routine urinalysis. All subjects were negative for HIV, HCV and HBV 
(except for serological scar). 
The study began and finished with 20 volunteers. The volunteers 
had the following clinical characteristics (according to gender and 
expressed as mean ± SD [range]): males: age: 32.40 ± 8.00 [23.00-
46.00], height: 1.73 ± 0.07 m [1.62-1.85], body weight: 72.48 ± 10.22 
[60.20-88.00]; females: age: 28.60 ± 9.54 [18.00-44.00], height: 1.60 
± 0.05 [1.54-1.70], body weight: 58.64 ± 6.09 [51.70-66.70]. All 
subjects provided written informed consent and the State University 
of Campinas - Unicamp approved the clinical protocol. The study 
was conducted in accordance with the provisions of the Declaration 
of Helsinki (1964), Tokyo (1975), Venice (1983), Hong Kong (1989), 
Somerset West (1996) and Edinburgh (2000) revisions [8]. 
The study was a single dose (5000 μg, 2.5 mL) gluteal intramuscular 
Citation: Mendes GD, Mendes FD, Sampaio MF, Silveira AS, Chen LS, et al. (2013) Hydroxocobalamin Quantification in Human Plasma by High-
Performance Liquid Chromatography Coupled with Electrospray Tandem Mass Spectrometry in a Pharmacokinetic Study. J Bioequiv 
Availab 5: 080-087. doi:10.4172/jbb.1000139
Volume 5(2): 080-087 (2013) - 083 
J Bioequiv Availab
ISSN:0975-0851 JBB, an open access journal
administration. The volunteers were hospitalized at 05:00 p.m. and 
received specialized assistance and care, including a brief investigation 
of their conditions upon confinement and at time of discharge, in 
order to evaluate their adherence to the requirements of the clinical 
protocol. Standard meals were administered at 07:00 p.m. (dinner) and 
10:00 p.m (snack). After an overnight fast (approximately 8 hours), 
they received at approximately 6:00 a.m. a dose (gluteal intramuscular) 
of alfa 5,6-dimethylbenzimidazolyl polypyrrolidone cobamide 
(Cronobê®)  injectable solution (5000 μg, 2.5 mL). All volunteers were 
required to remain fasting for 2 hours after dose administration, when 
a xanthine-free standard breakfast was available. A xanthine-free 
standard lunch was provided after five (lunch), eight (afternoon snack), 
twelve (dinner) and fifteen (night snack) hours after dose. After the 24-
hour blood withdrawal a standardized meal (breakfast) was served, and 
after a medical evaluation, volunteers were discharged and standard 
meal (lunch) of rice, beans, vegetables, and fried chicken plus a fruit 
as dessert was consumed. A morning, afternoon and evening snack 
was also provided consisting of crackers, bread, jelly, cakes and apples. 
No other food was permitted during the “in-house” period and liquid 
consumption was allowed ad libitum after lunch (with the exception 
of xanthine-containing drinks, including tea, coffee, and cola). At 
time intervals, systolic and diastolic arterial pressure (measured non-
invasively with a sphygmomanometer), heart rate and temperature 
were recorded. Blood samples (7 mL) from a suitable antecubital vein 
were collected at 1, 2, 3, 4, 5, 6, 12, 18, 24, 48, 72, 96, 120, 144 and 168 
post-dosing.
Formulation
The following formulation was employed: alfa 
5,6-dimethylbenzimidazolyl polypyrrolidone cobamide injectable 
solution (Cronobê®) 2.000 μg/mL (2.5 mL) manufactured by Biolab 
Sanus Farmacêutica Ltda (lot N° 802615, expiration: Feb/2010). 
Pharmacokinetic and statistical analysis
Non-compartmental analysis was also used to determine the 
pharmacokinetic parameters of cobalamin after the intramuscular 
administration. The Cmax and the time taken to achieve this 
concentration (Tmax) were obtained directly from the curves. The areas 
under the hydroxocobalamin plasma concentration vs. time curves 
from 0 to the last detectable concentration (AUClast) were calculated 
by applying the linear-log trapezoid rule [9]. Extrapolation of these 
areas to infinity (AUC0-inf) was done by adding the value Clast/ke to 
the calculated AUClast (where Clast=the last detectable concentration). 
Clearance (CL) was calculated by the formula dose/AUC0-inf. The AUC 
and CL were also calculated correcting the dose by weight (kg) and 
by surface area (m2) [10]. Cobalamin stability results were assessed 
for significance using Student’s t-test. The software used included 
WinNonLin Professional Network Edition (Pharsight, v. 5.3), 
Microsoft Excel (v. 7.0) and GraphPad Prism (v. 3.02).
Results and Discussion
This is the first HPLC-MS-MS method described for measuring 
hydroxocobalamin in biological fluids. The method was linear, 
calculating the calibration curve by a least-squares regression for 
hydroxocobalamin concentrations from 5 to 400 ng/mL (calibration 
curve equation: 0.0000136*x ± 0.000131, r=0.9983). 
The recovery of hydroxocobalamin was 38.2%, 37.5% and 33.5% for 
the 15.0, 80.0 and 320.0 ng/mL standard concentrations, respectively. 
The recovery of the internal standard was 75.1% for 1000.0 ng/mL 
concentration. The matrix effect of hydroxocobalamin was -21.2%, 
-40.3% and -40.0% for the 15.0, 80.0 and 320.0 ng/mL standard 
concentrations, respectively. The matrix effect of the internal standard 
was -33.3% for 1000.0 ng/mL concentration. The limit of quantification 
(LOQ), defined as the lowest concentration at which both the precision 
and accuracy were ± 20%, was 5.0 ng/mL. The within- and between-run 
precision and accuracy (with and without internal standard) for the 
LOQ and QCs are summarized in table 1.
The stability tests (Table 2) indicated no significant degradation 
under the conditions described above. No endogenous peak was 
observed in the mass chromatogram of blank plasma. The mass 
chromatograms of a sample are shown in figure 2, in which the 
retention times of both hydroxocobalamin and paracetamol were 1.55 
and 2.18, respectively. 
This is the first HPLC-MS-MS method developed for measuring 
hydroxocobalamin in human plasma. Hydroxocobalamin has been 
determined in human and rat plasma by isotopic dilution (LLOQ 34 
pg/mL) [4,5], in nutritive supplements and chlorella foods by capillary 
electrophoresis-inductively coupled plasma mass spectrometry 
(LLOQ 200 pg/mL, run-time 11 min) [6] and in ovine tissues by 
Intra-batch validation (n=7)
with 
IS
without IS
with 
IS
without IS
with 
IS
without IS
with 
IS
without IS
Nominal concentration (μg/mL) 5.0 15.0 80.0 320.0
Arithmetic mean (ug/mL) 5.4 5.1 15.0 14.9 79.2 78.0 316.9 295.9
Precision (CV%) 9.6% 9.2% 8.9% 8.2% 1.0% 1.8% 2.8% 1.5%
Accuracy (%) 108.9% 101.1% 99.9% 99.3% 98.9% 97.5% 99.0% 92.5%
Inter-batch (n=21)
with 
IS
without IS
with 
IS
without IS
with 
IS
without IS
with 
IS
without IS
Nominal concentration (μg/mL) 5.0 15.0 80.0 320.0
Arithmetic mean (ug/mL) 5.1 4.7 15.6 15.1 82.6 81.3 319.0 307.1
Precision (CV%) 9.4% 10.9% 6.9% 6.4% 4.6% 5.0% 5.5% 6.2%
Accuracy (%) 101.9% 94.4% 104.1% 101.2% 103.2% 101.6% 99.7% 96.0%
Table 1: Accuracy and precision data for hydroxocobalamin in human plasma.
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Post-processing stability test (ng/mL)
(n=5)
Reference values Values after 72 h 30 min Reference values
Values after 72 h 30 
min Reference values Values after 72 h 30 min
Low sample Medium sample High sample
Arithmetic Mean 16.7 16.2 80.5 75.3 300 275
CV (%) 1.8 3.9 2.1 13.4 2.6 3.2
Variation -3,0 -6.5 -8.3
Freeze-and-thaw stability test (ng/mL)
(n=5)
Reference values Values after 3 cycles Reference values Values after 3 cycles Reference values Values after 3 cycles
Low sample Medium sample High sample
Arithmetic Mean 13.1 11.8 57.6 52.2 196 185
CV (%) 4.8 6.2 3.1 4.0 8.9 1.5
Variation -9.9 -9.4 -5.6
Short-term stability test (ng/mL)
(n=5)
Reference values Values after 8 h 30 min Reference values
Values after 8 h 30 
min Reference values Values after 8 h 30 min
Low sample Medium sample High sample
Arithmetic Mean 13.1 11.7 57.6 50.5 196 170
CV (%) 4.8 5.1 3.1 5.3 8.9 3.7
Variation -10.7 -12.3 -13.3
Table 2: Stability quality control plasma samples (15.0, 80.0 and 320.0 ng/mL for hydroxocobalamin) to short-term (8 h 30 min) room temperature, three freeze/thaw (-20 
to 25°C) cycles and 72 h 30 min auto-sampler stability (6°C).
Analyte
 
 Low concentration 
Std solution Unextracted Extracted
11900 9470 3530
11700 9470 3540
11500 10000 3220
12000 8180 3570
11100 8750 3650
Mean 11640 9174 3502
CV (%) 3.1 7.8 4.7
Recovery 38.2
Matrix Effect -21.2
 
Medium concentration
Std solution Unextracted Extracted
68800 44800 16400
66700 41700 16400
73300 43800 16300
66900 42000 16000
86600 44000 16100
Mean 72460 43260 16240
CV (%) 11.5 3.1 1.1
Recovery 37.5
Matrix Effect -40.3
 
 High concentration
Std solution Unextracted Extracted
289000 180000 60600
289000 178000 60400
268000 176000 58200
289000 177000 59300
337000 172000 57000
Mean 294400 176600 59100
CV (%) 8.7 1.7 2.6
Recovery 33.5
Mattrix Effect -40.0
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Internal Standard Concentration
 Pool 1 Pool 2 Pool 3 Pool 1 Pool 2 Pool 3
Std solution Unextracted Extracted
756000 494000 500000 399000 327000 366000 311000
624000 482000 521000 407000 332000 381000 320000
650000 467000 475000 398000 318000 370000 313000
643000 419000 438000 404000 333000 340000 322000
682000 440000 445000 422000 329000 341000 330000
Mean 671000 460400 475800 406000 327800 359600 319200
CV (%) 7.7 6.7 7.4 2.4 1.8 5.1 2.4
Individual recoveries 71.2 75.6 78.6
Mean recovery 75.1
Mattrix effect -33.3
Table 3: Matrix effect between spiked mobile phase solutions and unextracted samples, spiked on plasma residues for analyte and internal standard.
Parameter Unit N Mean SD Min Median Max CV%
AUCinf ([ng*hr]/mL) 20 2467 765 839 2632 3496 30.99
AUClast ([ng*hr]/mL) 20 2044 641 729 2249 3218 31.36
Clast (ng/mL) 20 7.74 3.20 5.13 6.62 19.30 41.26
Cmax (ng/mL) 20 119.49 25.09 71.70 119.50 177.00 21.00
Ke (1/hr) 20 0.02 0.01 0.01 0.02 0.06 60.21
T1/2 (hr) 20 38.08 15.88 12.10 40.65 71.47 41.69
Tlast (hr) 20 90.00 24.47 48.00 96.00 120.00 27.19
Tmax (hr) 20 2.65 1.23 1.00 2.50 6.00 46.26
Vd (L) 20 111.71 33.42 54.68 114.00 164.42 29.91
CL (L/hr) 20 2.34 1.14 1.43 1.90 5.96 48.96
Table 4: Mean pharmacokinetic parameters obtained from 20 volunteers after administration of cobalamin formulation.
Male
 (Mean ± SD)
Female
 (Mean ± SD) t-test 
AUC ([ng*hr]/mL) 2382.96 ± 343.05 1705.59 ± 703.65 0.0136
corrected by weight (ug/kg) 34.07 ± 3.00 19.93 ± 8.18 0.0001
corrected by BSA (ug/m2) 0.88 ± 0.08 0.54 ± 0.21 0.0002
CL (L/hr) 1.76 ± 0.23 2.91 ± 1.41 0.0205
corrected by weight (L/hr*kg) 0.03 ± 0.003 0.06 ± 0.028 0.0036
corrected by BSA (L/hr*m2) 1.14 ± 0.09 2.14 ± 0.94 0.0036
Table 5: Average, SD and T-Test comparing clereance (CL) and AUClast against body surface area (BSA; m2) and weight (kg).
high-performance liquid chromatography (LLOQ 34 pg/mL, run-
time 10 min). Our method has good sensitivity (LLOQ of 5 ng/mL) 
for the objective of the study and can be carried out in a short time 
(RT of 1.55 min for hydroxocobalamin), permitting a high throughput. 
Furthermore, this method involves a very simple liquid-liquid 
extraction. 
Internal standards are routinely used in bioanalytical methods and 
HPLC-MS-MS has enough selectivity to allow the use of deuterated 
standards (Table 3). However, these standards are expensive and not 
easily available. Thus, they are commonly replaced by structurally 
related compounds. Considering that the extraction procedures for 
HPLC-MS-MS bioanalysis are very simple (protein precipitation is 
routinely employed), one should ask whether the use of structurally 
related internal standard is really required or advisable. The method 
described above validated well without the use of the internal standard, 
similar to other method [11]. Whether this approach applies to other 
bioanalytical methods should be further investigated. 
As demonstrated in this study, the present HPLC-MS-MS method 
is simple and selective for the determination of hydroxocobalamin 
in human plasma, thus it can be used for pharmacokinetic and 
bioequivalence studies of hydroxocobalamin.
The cobalamin was well tolerated and no significant adverse 
reactions were observed or reported. The mean hydroxocobalamin 
plasma concentrations vs. time profiles after intramuscular dose (5000 
μg) of cobalamin are shown in figure 3, respectively. Table 4 shows the 
mean pharmacokinetic parameters obtained from 20 volunteers after 
the administration of 5000 μg cobalamin. 
As expected, the mean hydroxocobalamin pharmacokinetic 
parameter for t1/2 (38.08 ± 15.88 hr) was higher than intravenous 
administration of cobalamin. (dose 2.5 g, t1/2=30.3 ± 2.4 hr; dose 5 g, 
t1/2=30.2 ± 6.7 hr; dose 7.5 g, t1/2=27.5 ± 2.5 hr; dose 10 g, t1/2=25.9 ± 
2.7 hr). No pharmacokinetic study has been performed comparing the 
influence of gender of the volunteer/patients [12]. 
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Figure 2:  MRM chromatograms of blank normal human plasma: (A) hydroxocobalamin and (B) paracetamol; MRM chromatogram of the LOQ: (C) hydroxocobalamin 
and (D) paracetamol.
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After intramuscular administration of the cobalamin 5000 ug 
to the volunteers, the AUC and Cl differ markedly by gender after 
administration of cobalamin 5000 μg. As, shown in the figure 4, the 
female volunteers presented significant (p=0.0136) lower AUC (1706 
± 704 ng.hr/mL) and larger (p=0.0205) clearance (2.91 ± 1.41 L/hr) 
as compared to male volunteers for AUC (2383 ± 343 ng.hr/mL) and 
clearance (1.76 ± 0.23 L/hr), respectively. The differences were present 
even the dose was corrected by either weight or body surface of the 
volunteer (Table 5). These pharmacokinetic differences could explain 
the higher prevalence of vitamin B12 deficiency in female patients [9].
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Figure 3: Hydroxocobalamin plasma mean concentrations vs. time profile 
obtained after intramuscular administration of 5000 μg of cobalamin 
formulation.
Figure 4: Pharmacokinetic parameters of the hydroxocobalamin for male 
and female. 
